Table:
Pre-screening	Screening	Baseline	Follow-up
Visit	1	2	3	4 (phone call only)
Assessmentsa	Within 3 months of baseline visit	Week −4 to −1	Day 0	Week 12 (+/− 7 days)	Week 24 (+/− 7 days)	Week 25 (+/− 3 days)
Identification and initial approach (including provision of PIS)	X
Eligibility criteria checked (as per routine clinical practice)	X
Written informed consent (including discussion of study in detail, questions answered)	X
Physical examination (height,e weight, blood pressure, pulse)	X	X
Venepuncture	Xb	Xc	Xd
Clinical history (relevant medical history, medication list/history)	X
Participant-completed questionnaires (ThyDQoL, ThySRQ, EQ-5D)	X	X
Nurse-administered questionnaires (FRAT, TUG)	X	X
Randomization (after all eligibility criteria checked and written informed consent obtained)	X
Study medication prescribed and dispensed (following LT4 dose assessment at visit 2 only)	X	X
Study medication compliance checks	X	X
Concomitant medication	X	X	X
Adverse events	X	X
Serious adverse events	X	X	X

What are the following image content in markdown style: |  | Pre-screening | Screening | Baseline | <COLSPAN=3> Follow-up | 
 | Visit |  |  | 1 | 2 | 3 | 4 (phone call only) | 
 | Assessmentsa | Within 3 months of baseline visit | Week −4 to −1 | Day 0 | Week 12 (+/− 7 days) | Week 24 (+/− 7 days) | Week 25 (+/− 3 days) | 
 | --- | --- | --- | --- | --- | --- | --- | 
 | Identification and initial approach (including provision of PIS) | X |  |  |  |  |  | 
 | Eligibility criteria checked (as per routine clinical practice) | X |  |  |  |  |  | 
 | Written informed consent (including discussion of study in detail, questions answered) |  | X |  |  |  |  | 
 | Physical examination (height,e weight, blood pressure, pulse) |  |  | X |  | X |  | 
 | Venepuncture |  |  | Xb | Xc |

Xd |  | 
 | Clinical history (relevant medical history, medication list/history) |  |  | X |  |  |  | 
 | Participant-completed questionnaires (ThyDQoL, ThySRQ, EQ-5D) |  |  | X |  | X |  | 
 | Nurse-administered questionnaires (FRAT, TUG) |  |  | X |  | X |  | 
 | Randomization (after all eligibility criteria checked and written informed consent obtained) |  |  | X |  |  |  | 
 | Study medication prescribed and dispensed (following LT4 dose assessment at visit 2 only) |  |  | X | X |  |  | 
 | Study medication compliance checks |  |  |  | X | X |  | 
 | Concomitant medication |  |  | X | X | X |  | 
 | Adverse events |  |  |  | X | X |  | 
 | Serious adverse events |  |  |  | X | X | X |